← Back to Search

Unknown

HSY244 for Atrial Fibrillation

Phase 2
Waitlist Available
Research Sponsored by Novartis Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 (0 min (pre-dose), 15 min (end of infusion), 30 min , 60 min, 90 min and 180 min) and day 5
Awards & highlights

Study Summary

This trial will study the effects of HSY244 on AF and HF patients.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 (0 min (pre-dose), 15 min (end of infusion), 30 min , 60 min, 90 min and 180 min) and day 5
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 (0 min (pre-dose), 15 min (end of infusion), 30 min , 60 min, 90 min and 180 min) and day 5 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants With Conversion to Sinus Rhythm for at Least 1 Minute Within 90 Minutes From the Start of Study Drug Administration.
Secondary outcome measures
Area Under the Plasma Concentration-time Curve (AUClast)
Maximum Observed Plasma Concentration (Cmax)
Time to Reach the Maximum Concentration After Drug Administration (Tmax)

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: HSY244Experimental Treatment1 Intervention
HSY244 150 mg concentrate solution for injection via intravenous infusion
Group II: PlaceboPlacebo Group1 Intervention
Placebo concentrate solution for injection via intravenous infusion

Find a Location

Who is running the clinical trial?

Novartis PharmaceuticalsLead Sponsor
2,855 Previous Clinical Trials
4,197,337 Total Patients Enrolled
1 Trials studying Atrial Fibrillation

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation
2020. "A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04582409.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top